January 2, 2018 / 1:11 PM / 2 months ago

BRIEF-Seattle Genetics says FDA grants its Hodgkin Lymphoma treatment priority review status

Jan 2 (Reuters) - Seattle Genetics Inc:

* FDA ACCEPTS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION AND GRANTS PRIORITY REVIEW FOR ADCETRIS® (BRENTUXIMAB VEDOTIN) IN FRONTLINE ADVANCED HODGKIN LYMPHOMA

* SEATTLE GENETICS INC - FDA GRANTED PRIORITY REVIEW FOR APPLICATION, AND PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE IS MAY 1, 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below